Skip to main content

Table 2 Positive results of serology, in-house mPCR, and commercial PCR classified by atypical bacteria

From: Comparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria

Techniques Group 1a NPS Group 2b NPA Group 3c NPS and IS Group 4d NPS
M. pneumoniae n (%) n (%) n (%) n (%)
 Serology 5/46 (10.9) 4/77 (5.2) 21/48 (43.8) 2/19 (10.5)
 mPCR 1/68 (1.5) 0/88 (0) NPS: 7 (14.3)
IS: 18 (36.7)
0/20 (0)
 Commercial PCR
[Trade mark]
4/68 (5.9)
[Speed-oligo]
1/88 (1.4)
[Speed-oligo]
13/49 (26.5)
[Seeplex]
0/20 (0)
[Speed-oligo]
C. pneumoniae
 Serology 3/46 (6.5) 9/77 (11.7) 6/48 (12.5) 4/19 (21.1)
 mPCR 0/68 (0) 0/88 (0) NPS: 0 (0)
IS: 0 (0)
0/20 (0)
 Commercial PCR 0/68 (0) 1/88 (1.4) 0/49 (0) 0/20 (0)
L. pneumophila
 Serology 3/46 (6.5) 2/77 (2.6) 5/48 (10.4) 0/19 (0)
 mPCR 0/68 (0) 0/88 (0) NPS: 0 (0)
IS: 0 (0)
1/20 (5.0)
 Commercial PCR 2/68 (2.9) 0/88 (0) 0/49 (0) 4/20 (21)
  1. NPS Nasopharyngeal swab, NPA Nasopharyngeal aspirate, IS Induced sputum
  2. aProspective adults with community-acquired pneumonia (CAP). Speed-Oligo® was run as commercial PCR on the NPSs
  3. bRetrospective adults with CAP. Speed-Oligo® was run as commercial PCR on the NPAs
  4. cChildren with CAP. Seeplex® PneumoBacter was run as a commercial PCR on IS
  5. dIndividuals without CAP. Speed-oligo® was run as a commercial PCR on NPSs